Efficacy of surgical treatment for brain metastasis in patients with non-small cell lung cancer

PURPOSE: Patients with non-small cell lung cancer (NSCLC) and simultaneously having brain metastases at the initial diagnosis, presenting symptoms related brain metastasis, survived shorter duration and showed poor quality of life. We analyzed our experiences on surgical treatment of brain metastasis in patients with NSCLC. MATERIALS AND METHODS: We performed a single-center, retrospective review of 36 patients with NSCLC and synchronous brain metastases between April 2006 and December 2011. Patients were categorized according to the presence of neurological symptoms and having a brain surgery. As a result, 14 patients did not show neurological symptoms and 22 patients presented neurological symptoms. Symptomatic 22 patients were divided into two groups according to undergoing brain surgery (neurosurgery group; n=11, non-neurosurgery group; n=11). We analyzed overall surgery (OS), intracranial progression-free survival (PFS), and quality of life. RESULTS: Survival analysis showed there was no difference between patients with neurosurgery (OS, 12.1 months) and non-neurosurgery (OS, 10.2 months; p=0.550). Likewise for intracranial PFS, there was no significant difference between patients with neurosurgery (PFS, 6.3 months) and non-neurosurgery (PFS, 5.3 months; p=0.666). Reliable neurological one month follow up by the Medical Research Council neurological function evaluation scale were performed in symptomatic 22 patients. The scale improved in eight (73%) patients in the neurosurgery group, but only in three (27%) patients in the non-neurosurgery group (p=0.0495). CONCLUSION: Patients with NSCLC and synchronous brain metastases, presenting neurological symptoms showed no survival benefit from neurosurgical resection, although quality of life was improved due to early control of neurological symptoms.ope

A Study on the Korean tradition of popular tragic drama in 1930`s

학위논문(박사)--서울대학교 대학원 :국어국문학과 현대문학전공,1998.Docto

역형성 신경교종에서 생존율과 예후인자 분석 및 2016 WHO 분류의 예후적 의의

Objective To investigate the survival and prognostic factors in anaplastic gliomas and whether the updated 2016 WHO classification in anaplastic gliomas has more prognostically predictive impact for survival than 2007 WHO classification. Methods A total of 113 consecutive patients with newly diagnosed anaplastic gliomas by 2007 WHO classification at our hospital from Jan. 2001 to Dec. 2013 were enrolled in this study. We integrated the molecular profiles in each patient and reclassified the diagnosis with the molecular information according to 2016 WHO classification. The Kaplan Meier methods, a multivariate Cox proportional regression analysis, Contal and O’Quigley method and a time-dependent ROC curve method were used for statistical analysis. Results The overall survival of total group of anaplastic gliomas was 48.4 months, of which the AA, IDH-wildtype group was 21.5 months. The progression free survival of total group was 31.8 months, of which the AA, IDH-wildtype group was 16.4 months. Age, postoperative tumor volume, extent of resection measured in T2-weighted MRI, and deep location of tumor were factors associated with the overall survival. And cut off value of tumor resection were 99.96% in contrast enhanced T1-weighted MRI and 85.64% in T2-weighted MRI. The 2016 WHO classification significantly increased predictability for survival across the entire follow-up period. The difference (iAUC of 2016 model – iAUC of 2007 model) was statistically significant (estimated difference was 0.024, 95% CI is 0.022–0.075). Conclusion We investigated the survival and prognostic factors in anaplastic gliomas and showed that 2016 WHO classification of tumors of the CNS may be more predictable in survival than 2007 WHO classification in patients with anaplastic gliomas.open석